Leica Biosystems Launches HistoCore CHROMAX Workstation, Advancing its Coverslipping and Staining Portfolio

January 28, 2025 – Nussloch, Germany. Leica Biosystems, a global leader in anatomic pathology, is known for its high-quality histology solutions. Today, the company announced the next iteration in its staining and coverslipping portfolio, the HistoCore CHROMAX Workstation (WS).

Today, many laboratories must manually keep a record of how many slides have gone through their histology stainers to know when it’s time to replace reagents. The HistoCore CHROMAX WS automates this process with a reagent management system, enabling technicians to focus their limited time elsewhere.

The HistoCore CHROMAX WS brings staining and coverslipping into the modern age with graphical, touch-screen interfaces, making it a breeze for technicians to adjust settings and track staining progress.

“This new workstation is the culmination of more than 150 years of innovation,” said Hermann Hopermann, Senior Director of R&D for Core Histology at Leica Biosystems. “Customers can expect high-quality results for both routine and special stains with the HistoCore CHROMAX WS.”

HistoCore CHROMAX WS is available in select countries. Consult your local representative for details.

For In Vitro Diagnostic Use

About Leica Biosystems 
Leica Biosystems is a cancer diagnostics company and a global leader in anatomic and digital pathology solutions. The company offers a comprehensive product range for each step in the pathology process, from sample preparation and staining to imaging and reporting. As the only company to own the full workflow from biopsy to diagnosis, Leica Biosystems is uniquely positioned to break down the barriers between each step. The company’s mission of “Advancing Cancer Diagnostics, Improving Lives” is at the heart of its corporate culture. Leica Biosystems is proud to be a Danaher Corporation subsidiary.